Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial
Andrew A Lover
doi:10.1101/2020.03.22.20040949
The author stands by all analytical and statistical aspects of this preprint. However, subsequent to this analysis, further details of the original study have been released-with major uncertainties in study design, reporting, choice of endpoints, and most importantly, data integrity [1, 2] . Therefore, all results from the original study should be viewed with considerable skepticism.
References
Bik, Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections
Coveney, Firthlogit: Stata module to calculate bias reduction in logistic regression
Gautret, Lagier, Parola, Van Thuan, Hoang et al., Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial, medRxiv
Ian R White, Horton, Carpenter, Pocock, Strategy for intention to treat analysis in randomised trials with missing outcome data, Bmj
Lorenc, Oliver, Adverse effects of public health interventions: a conceptual framework, J Epidemiol Community Health
Mcnutt, Wu, Xue, Hafner, Estimating the relative risk in cohort studies and clinical trials of common outcomes, American journal of epidemiology
Michael A Johansson, Reich, Meyers, Lipsitch, Preprints: An underutilized mechanism to accelerate outbreak science, PLoS medicine
Nakagawa, Innes, Cuthill, Effect size, confidence interval and statistical significance: a practical guide for biologists, Biological reviews
Pubpeer, Pubpeer: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
Rivers, Chretien, Riley, Pavlin, Woodward et al., Using "outbreak science" to strengthen the use of models during epidemics, Nature Communications
Royston, Parmar, Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Statistics in medicine
Sandeep, Gupta, Intention-to-treat concept: a review, Perspectives in clinical research
Tjur, Coefficients of determination in logistic regression models-a new proposal: The coefficient of discrimination, The American Statistician
DOI record:
{
"DOI": "10.1101/2020.03.22.20040949",
"URL": "http://dx.doi.org/10.1101/2020.03.22.20040949",
"abstract": "<jats:title>A<jats:sc>bstract</jats:sc></jats:title><jats:p>Human infections with a novel coronavirus (SARS-CoV-2) were first identified via syndromic surveillance in December of 2019 in Wuhan China. Since identification, infections (coronavirus disease-2019; COVID-19) caused by this novel pathogen have spread globally, with more than 250,000 confirmed cases as of March 21, 2020. An open-label clinical trial has just concluded, suggesting improved resolution of viremia with use of two existing therapies: hydroxychloroquine (HCQ) as monotherapy, and in combination with azithromycin (HCQ-AZ). [3, 4].</jats:p><jats:p>The results of this important trial have major implications for global policy in the rapid scale-up and response to this pandemic. The authors present results with p-values for differences in proportions between the study arms, but their analysis is not able to provide effect size estimates.</jats:p><jats:p>To address this gap, more modern analytical methods including survival models, have been applied to these data, and show modest to no impact of HCQ treatment, with more significant effects from the HCQ-AZ combination, potentially suggesting a role for co-infections in COVID-19 pathogenesis.</jats:p><jats:p>The trial of Gautret and colleagues, with consideration of the effect sizes, and p-values from multiple models, does not provide sufficient evidence to support wide-scale rollout of HCQ monotherapy for the treatment of COVID-19; larger randomized studies should be considered. These data also suggest further randomized-controlled studies of HCQ-AZ combination therapy should be undertaken.</jats:p>",
"accepted": {
"date-parts": [
[
2020,
4,
10
]
]
},
"author": [
{
"ORCID": "http://orcid.org/0000-0002-2181-3559",
"affiliation": [],
"authenticated-orcid": false,
"family": "Lover",
"given": "Andrew A.",
"sequence": "first"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
3,
27
]
],
"date-time": "2020-03-27T17:55:42Z",
"timestamp": 1585331742000
},
"deposited": {
"date-parts": [
[
2020,
11,
21
]
],
"date-time": "2020-11-21T20:01:13Z",
"timestamp": 1605988873000
},
"group-title": "Epidemiology",
"indexed": {
"date-parts": [
[
2023,
6,
23
]
],
"date-time": "2023-06-23T14:10:26Z",
"timestamp": 1687529426946
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 14,
"issued": {
"date-parts": [
[
2020,
3,
27
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2020.03.22.20040949",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2020,
3,
27
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2020,
3,
27
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"key": "2020112112000956000_2020.03.22.20040949v2.1",
"unstructured": "Elisabeth Bik. Thoughts on the Gautret et al. paper about Hydroxychloroquine and Azithromycin treatment of COVID-19 infections. Technical report, March 2020. Library Catalog: scienceintegritydigest.com."
},
{
"key": "2020112112000956000_2020.03.22.20040949v2.2",
"unstructured": "Pubpeer. Pubpeer: Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial, March 2020."
},
{
"key": "2020112112000956000_2020.03.22.20040949v2.3",
"unstructured": "Hydroxychloroquine and azithromycin as a treatment of COVID-19 – IHU. Library Catalog: www.mediterranee-infection.com."
},
{
"key": "2020112112000956000_2020.03.22.20040949v2.4"
},
{
"DOI": "10.1136/bmj.d40",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.5"
},
{
"DOI": "10.4103/2229-3485.83221",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.6"
},
{
"DOI": "10.1111/j.1469-185X.2007.00027.x",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.7"
},
{
"DOI": "10.1198/tast.2009.08210",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.8"
},
{
"DOI": "10.1093/aje/kwg074",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.9"
},
{
"DOI": "10.1002/sim.1203",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.10"
},
{
"key": "2020112112000956000_2020.03.22.20040949v2.11",
"unstructured": "Joseph Coveney . Firthlogit: Stata module to calculate bias reduction in logistic regression. 2015."
},
{
"article-title": "Using “outbreak science” to strengthen the use of models during epidemics",
"first-page": "1",
"issue": "1",
"journal-title": "Nature Communications",
"key": "2020112112000956000_2020.03.22.20040949v2.12",
"volume": "10",
"year": "2019"
},
{
"DOI": "10.1136/jech-2013-203118",
"doi-asserted-by": "publisher",
"key": "2020112112000956000_2020.03.22.20040949v2.13"
},
{
"DOI": "10.1371/journal.pmed.1002549",
"doi-asserted-by": "crossref",
"key": "2020112112000956000_2020.03.22.20040949v2.14",
"unstructured": "Michael A Johansson , Nicholas G Reich , Lauren Ancel Meyers , and Marc Lipsitch . Preprints: An underutilized mechanism to accelerate outbreak science. PLoS medicine, 15(4), 2018."
}
],
"reference-count": 14,
"references-count": 14,
"relation": {},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2020.03.22.20040949"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"subtype": "preprint",
"title": "Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial",
"type": "posted-content"
}